Batavia Bioservices and UvA Holding announce STEP(TM) technology exclusive license
(Thomson Reuters ONE) -
Batavia Bioservices BV and UvA Holding BV announced today that they have
successfully concluded an agreement granting Batavia Bioservices the exclusive
rights to STEP(TM) technology developed by scientists at CellaGenics BV, an UvA
Holding BV company.
Under the agreement, Batavia Bioservices has been granted the exclusive license
to the STEP(TM) technology, a revolutionary, plasmid-based system that
significantly reduces the time required to develop recombinant protein-producing
mammalian cell lines while increasing protein production more then 10-fold.
Menzo Havenga (CEO Batavia Bioservices) commented: "We are very pleased that UvA
Holding has selected Batavia Bioservices as its marketing partner for STEP(TM)
technology since we firmly believe that this technology will significantly
reduce manufacturing costs. Chris Yallop (COO Batavia Bioservices) added:
"STEP(TM) technology also allows the development of so-called rare diseases
biopharmaceutical products, which have always been considered too expensive to
develop. Piet Scholten (Director UvA Holding BV) concluded: "With their in-depth
know how in biopharm manufacturing, vast network, and presence in both Europe
and USA, Batavia Bioservices provided the ideal landing platform for marketing
our technology and we look forward to a fruitful relationship!"
Financial details of the exclusive license agreement were not disclosed
About Batavia Bioservices BV
Batavia Bioservices is a biopharmaceutical process & product development
services company, dedicated to add value to its customers by providing high
quality biopharmaceuticals for proof-of-concept studies as well as pre-clinical
and clinical materials. The company, headquartered in Leiden the Netherlands has
in-depth know how regarding manufacturing of recombinant proteins, antibodies
and vaccines. For more information please visit us at
www.Bataviabioservices.com.
About UvA Holding BV
UvA Holding is a private company and a 100% subsidiary of University of
Amsterdam. The company develops, implements and manages market-oriented
activities which are non-core but at the same time directly related to the
university.
Contact:
Chris Yallop
c.yallop(at)bataviabioservices.com
Phone: +31 (0) 888 66 96 76)
Menzo Havenga
m.havenga(at)bataviabioservices.com
Phone: +31 (0) 888 66 96 42)
Batavia Bioservices and UvA Holding announce STEP technology exclusive:
http://hugin.info/148797/R/1696862/559014.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Batavia Bioservices B.V. via Thomson Reuters ONE
[HUG#1696862]
Unternehmensinformation / Kurzprofil:
Datum: 29.04.2013 - 08:00 Uhr
Sprache: Deutsch
News-ID 253679
Anzahl Zeichen: 3478
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 197 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Batavia Bioservices and UvA Holding announce STEP(TM) technology exclusive license"
steht unter der journalistisch-redaktionellen Verantwortung von
Batavia Bioservices B.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
